| 國立臺灣大學 |
1952 |
Atempt to Synthesige 5.6.7.8.2'.3'.4'.5'.6'-Nonahydroxyflavone
|
廖宗凱 |
| 臺北醫學大學 |
1994 |
Atenolol前驅藥之製備研究
|
林友慈 |
| 臺北醫學大學 |
2004 |
Atenolol與Carvedilol於高血壓大白鼠大動脈內皮細胞隙連結之差異性作用
|
李秉穎; Ping-Ying Lee |
| 國立臺灣大學 |
2010 |
AtERF1及AIL7在非生物性逆境耐受性上分別扮演的角色
|
郭瑋文; Kuo, Wei-Wen |
| 朝陽科技大學 |
2022-12-09 |
ATERRA
|
陳奕如;潘妏婷;李岱樺;蔡宜軒;張雨薇;黃沛儒 |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply
|
Finn R.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-14T23:18:53Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang, Yulei; Lu, Li Chun; Guan, Yinghui; MING-CHIH HO; Lu, Shan; Spahn, Jessica; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-07T03:29:02Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang Y.; Lu L.-C.; Guan Y.; Ho M.-C.; Lu S.; Spahn J.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-11-25T02:38:28Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang, Yulei; Lu, Li-Chun; Guan, Yinghui; MING-CHIH HO; Lu, Shan; Spahn, Jessica; Hsu, Chih-Hung |
| 國家衛生研究院 |
2021-07 |
Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load
|
Chen, S;Lai, H;Tsou, H;Shao, Y;Chang, C;Su, T;Liu, T;Chen, L;Cheng, A;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Chih-Hung Hsu;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chih-Hung Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIH-HUNG HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 國家衛生研究院 |
2025-01 |
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
|
Wu, SG;Ho, CC;Yang, JC;Yu, SH;Lin, YF;Lin, SC;Liao, BC;Yang, CY;Lin, YT;Yu, CJ;Chuang, YT;Liao, WY;Yap, KY;Kou, WS;Shih, JY |
| 臺北醫學大學 |
2014 |
ATF3 PROTECT AGAINST PRESSURE OVERLOAD HEART FAILURE VIA BECLIN-1 PATHWAY
|
Cheng, C.F.;Li, S.F.;Lin, H. |
| 臺北醫學大學 |
2013 |
ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression
|
PF, Lia;CF, Cheng;Lin, H;TL, Tseng;HH, Chen;SH, Chen |
| 臺北醫學大學 |
2013 |
ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression
|
Lia, PF;Cheng, CF;Lin, H;Tseng, TL;Chen, HH;Chen, SH |
| 臺北醫學大學 |
2014 |
ATF3 Protects Against Pressure Overload Heart Failure Via Autophagy Molecule Beclin-1 Pathway
|
Lin, H;HF, Li;HH, Chen;PF, Lai;SH, Juan;JJ, Chen;CF, Cheng |
| 臺北醫學大學 |
2014 |
ATF3 Protects Against Pressure Overload Heart Failure Via Autophagy Molecule Beclin-1 Pathway
|
Lin, H;Li, HF;Chen, HH;Lai, PF;Juan, SH;Chen, JJ;Cheng, CF. |
| 臺北醫學大學 |
2021-04 |
ATF3-Expressing Large-Diameter Sensory Afferents at Acute Stage as Bio-Signatures of Persistent Pain Associated with Lumbar Radiculopathy
|
Jiann Her Lin, Yu Wen Yu, Yu Chia Chuang, Cheng Han Lee, Chih Cheng Chen; 林建和 |
| 臺大學術典藏 |
2022-09-05T06:38:52Z |
ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis
|
TZU-MING JAO; Nangaku M.; Wu C.-H.; Sugahara M.; Saito H.; Maekawa H.; Ishimoto Y.; Aoe M.; Inoue T.; Tanaka T.; Staels B.; Mori K.; Inagi R. |
